The general counsel of a Basel-based biotech company receives a discovery request from opposing counsel in Southern District of New York product liability litigation. The request seeks "all documents relating to the safety profile of [the product], including communications with legal counsel regarding regulatory submissions." The company's files in Switzerland contain precisely such communications: safety discussions with external Swiss patent attorneys, regulatory strategy memos from the company's Swiss Rechtsanwalt, and mixed business-legal documents prepared for board presentations. The general counsel's own files may also be relevant, but whether those files carry professional secrecy protection depends on a threshold question the company may never have examined.
Producing protected documents may violate Art. 321 of the Swiss Criminal Code. Withholding them may result in adverse inference instructions, monetary sanctions, or default judgment in the US proceeding. The company's US litigation counsel asks for guidance. Swiss counsel provides an answer that satisfies no one: both options carry legal risk, and the analysis begins with a question about corporate legal department structure that most companies have never considered.
1. Where Do Swiss Secrecy and US Discovery Collide?
The conflict between Swiss professional secrecy and US discovery obligations is not new, but it has intensified as life sciences companies increasingly operate across both jurisdictions. Pharmaceutical product liability litigation, patent disputes, securities class actions, and government investigations routinely generate discovery demands that reach Swiss-held documents. The Federal Rules of Civil Procedure permit discovery of any nonprivileged matter relevant to a party's claim or defense, and US courts assert broad authority to compel production of documents held abroad by parties subject to their jurisdiction.1Fed R Civ P 26(b)(1); Société Nationale Industrielle Aérospatiale v US District Court, 482 US 522 (1987).
Switzerland, meanwhile, maintains one of the world's strongest professional secrecy regimes. The Berufsgeheimnis (professional secrecy) is not merely an evidentiary privilege that can be waived at the client's convenience. It is a criminal law obligation imposed on certain professionals, breach of which constitutes a criminal offense punishable by imprisonment.2Schweizerisches Strafgesetzbuch (StGB) vom 21. Dezember 1937 (SR 311.0), Art. 321. The professionals bound by this obligation include attorneys (Rechtsanwälte), patent attorneys, notaries, auditors, physicians, and pharmacists, categories that overlap substantially with the advisors life sciences companies regularly consult.
A company caught between Swiss criminal law and US discovery procedure cannot comply with both legal systems simultaneously, and both threaten consequences for following the other's rules.
The collision is structural. US discovery law assumes that parties control their documents and can produce them unless a recognized privilege applies. Swiss law assumes that certain communications are protected by obligations that run to the professional as well as the client. Art. 321(2) StGB provides that disclosure is permissible with client consent or, alternatively, with written authorization from the superior authority or supervisory authority, but commentary emphasizes that registered attorneys bear an independent duty to maintain secrecy and may decline to disclose even with client consent unless the circumstances clearly justify release.3Art. 321(2) StGB; Bundesgesetz über die Freizügigkeit der Anwältinnen und Anwälte (Anwaltsgesetz, BGFA) vom 23. Juni 2000 (SR 935.61), Art. 13. These frameworks do not accommodate each other. A company caught between them faces genuine legal jeopardy in both directions.
2. What Does Swiss Professional Secrecy Protect?
Art. 321 of the Swiss Criminal Code (Strafgesetzbuch, StGB) establishes the criminal offense of breach of professional secrecy. The provision applies to clergy, attorneys, defense counsel, notaries, patent attorneys, auditors bound to secrecy under the Code of Obligations, physicians, dentists, chiropractors, pharmacists, midwives, psychologists, nurses, physiotherapists, occupational therapists, dieticians, optometrists, osteopaths, and their auxiliaries. Any person in these categories who "divulges a secret that has been confided to them by virtue of their profession or that they have perceived in the exercise of their profession" commits an offense punishable by imprisonment of up to three years or a monetary penalty.4Art. 321(1) StGB. Critically, Art. 321 is an Antragsdelikt (complaint offense): prosecution requires a criminal complaint from the person whose secret was disclosed and is not initiated ex officio by Swiss authorities. This procedural requirement materially affects the practical risk calculus: the affected professional's client or patient must actively seek prosecution.
The scope of protection extends beyond what common law jurisdictions typically recognize as attorney-client privilege. Swiss professional secrecy covers not only the content of communications but also the fact that a professional relationship exists. It protects not only legal advice but also factual information learned in the course of the professional relationship. The "secret" need not be explicitly designated as confidential; anything learned in the professional context is presumptively protected unless the information is already publicly known. The Federal Tribunal has interpreted Art. 321 StGB broadly: in BGE 117 Ia 341, the Court emphasized that professional secrecy extends to all facts confided to the lawyer that bear any connection to the professional relationship, however tenuous (fort ténu). The corollary limitation appears in BGE 112 Ib 606, where the Court held that activities where the commercial element predominates (such as investment management) fall outside the scope of protected attorney activity, though that exclusion is qualified rather than categorical: asset management incidental to a genuine legal mandate, such as an estate or matrimonial-property division, can remain covered. The distinction is highly relevant to life sciences companies where counsel may perform mixed functions.5BGE 117 Ia 341 E. 6a/bb; BGE 112 Ib 606. These interpretations, extending protection beyond what US attorney-client privilege would cover, increase the potential for conflict when US discovery reaches Swiss-held materials.
For life sciences companies, this breadth creates both protection and complexity. Communications with Swiss patent attorneys regarding freedom-to-operate analyses, regulatory submissions, or litigation strategy fall within Art. 321's scope. So do discussions with Swiss medical advisors about product safety or clinical trial design. Documents prepared by these professionals, or prepared by the company for transmission to these professionals, may carry protection that Swiss law does not permit the company to unilaterally waive.
Art. 321 StGB must be distinguished from banking secrecy under Art. 47 of the Banking Act (Bankengesetz, BankG).6Bundesgesetz über die Banken und Sparkassen (Bankengesetz, BankG) vom 8. November 1934 (SR 952.0), Art. 47. Both impose criminal sanctions for unauthorized disclosure, but they protect different populations: Art. 47 binds bank employees and agents, while Art. 321 binds enumerated professionals in the context of the professional relationship. In life sciences disputes, Art. 321 is the primary concern, yet US counsel sometimes cite "Swiss secrecy" generically, conflating the two regimes in ways that undermine the specificity comity analysis requires.
A foundational question: does Art. 321 StGB apply only to disclosures made on Swiss territory? Under Art. 3 and 8 StGB read together, Swiss criminal law applies where either the act or the result occurs (the Ubiquitätsprinzip).7Art. 3 i.V.m. Art. 8 StGB (Ubiquitätsprinzip); see Donatsch/Tag, Strafrecht I (9th edn, Schulthess 2013) § 6 N 5 ff. The prevailing doctrinal view holds that Art. 321 protects the secret itself, and that the punishable conduct is the disclosure committed by the Swiss-based secrecy holder, so the place of commission (Begehungsort) lies in Switzerland regardless of where the recipient sits. Disclosure to the professional's own auxiliaries (Hilfspersonen), themselves bound by Art. 321, is generally not a punishable revelation; but transmitting protected material to a separate non-Swiss affiliate or foreign counsel may itself constitute the punishable disclosure, so routing production offshore does not reliably avoid Art. 321 exposure.
Art. 321(2) permits disclosure with client consent or written authorization from the cantonal superior authority or supervisory authority (vorgesetzte Behörde oder Aufsichtsbehörde),8Art. 321(2) StGB. but complications arise: when the client is a corporation, who speaks for it? When the client relationship has ended, can former clients be located? When the supervisory authority route is necessary, the authorization process is not automatic; the authority must balance the interests in disclosure against the interests protected by secrecy.
The Anwaltsgesetz reinforces these protections. Under Art. 13 BGFA, even where the client consents to disclosure (removing criminal liability under Art. 321(2) StGB), the attorney retains independent discretion to decline, creating a dual-key structure where client consent is necessary but may not be sufficient.9Art. 13 BGFA.
3. Does In-House Counsel Receive the Same Protection?
A threshold question arises for in-house legal departments, one that many life sciences companies have never examined. Swiss professional secrecy under Art. 321 StGB does not automatically extend to corporate counsel (Unternehmensjuristen). The criminal law protection applies to attorneys registered with a cantonal bar and practicing as Rechtsanwälte. An in-house lawyer holding a law degree but not registered as a practicing attorney, common in multinational corporate structures, does not enjoy Art. 321 protection for communications with that lawyer.
The Swiss Civil Procedure Code revision effective 1 January 2025 introduced a separate protection: Art. 167a ZPO grants in-house counsel a right to refuse cooperation in Swiss civil proceedings under specified conditions.10Schweizerische Zivilprozessordnung (ZPO) vom 19. Dezember 2008 (SR 272), Art. 167a (effective 1 January 2025). The company must be registered in the Swiss Commercial Register (or comparable foreign register), the head of the legal department must hold a Swiss attorney's license or equivalent foreign qualification, and the activity in question would be considered part of a lawyer's typical professional activities (berufsspezifisch). Where these conditions are met, companies may refuse to produce documents from the in-house legal department in Swiss civil proceedings, and in-house lawyers may refuse to testify as witnesses.
The distinction is critical for cross-border discovery. Art. 321 imposes criminal sanctions and applies to registered external counsel regardless of forum. Art. 167a grants a procedural right in Swiss civil proceedings only; it does not extend to criminal or administrative proceedings, must be affirmatively invoked, and does not create criminal exposure for disclosure. A company assuming that in-house counsel communications carry the same protection as external counsel communications may find that the protection differs in scope, conditions, and consequences of breach. The level of protection depends on organizational choices (whether the head of the legal department holds a bar registration, whether activities are documented as berufsspezifisch) that must be examined before the discovery dispute creates urgency.
Work product considerations add further complexity. US work product doctrine under Fed R Civ P 26(b)(3) protects materials prepared in anticipation of litigation, subject to qualified immunity.11Fed R Civ P 26(b)(3). Swiss professional secrecy does not depend on whether materials were prepared in anticipation of litigation; it protects all information learned in the professional relationship. The categorical difference (one litigation-focused and qualified, the other relationship-focused and absolute) requires document-by-document analysis in cross-border disputes.
Professional secrecy under Art. 321 StGB thus addresses the content of what may be disclosed. Art. 167a ZPO extends a narrower procedural protection to qualifying in-house counsel. And Art. 271 StGB (the "blocking statute") addresses the process by which disclosure occurs, potentially criminalizing the very act of gathering documents in Switzerland for production in foreign proceedings.
4. How Far Does US Discovery Reach?
The following discussion of US discovery procedure and comity standards is for informational purposes. Companies facing specific cross-border discovery disputes should consult US-qualified counsel.
US civil procedure grants litigants broad discovery rights. The Federal Rules permit discovery of any nonprivileged matter relevant to any party's claim or defense and proportional to the needs of the case.12Fed R Civ P 26(b)(1). Courts routinely order production of documents held abroad when the producing party is subject to the court's jurisdiction.
The Supreme Court's decision in Société Nationale Industrielle Aérospatiale v United States District Court established the governing framework.13Société Nationale Industrielle Aérospatiale (n 1) 544. The Court rejected a mandatory Hague Convention requirement, directing district courts to conduct a comity analysis weighing the interests of both sovereigns. The Restatement (Third) of Foreign Relations Law identifies relevant factors: the importance of the documents, the specificity of the request, whether information originated in the United States, the availability of alternative means of securing the information, and the extent to which noncompliance would undermine US interests versus compliance would undermine foreign state interests.14Restatement (Third) of Foreign Relations Law § 442(1)(c) (1987). Swiss professional secrecy receives weight in this analysis, but not dispositive weight.
The consequences for non-compliance can be severe. Rule 37 authorizes orders deeming facts established, monetary penalties, evidence preclusion, and default judgment.15Fed R Civ P 37(b)(2)(A). Swiss-specific and analogous foreign-secrecy precedents, including In re Grand Jury Subpoena (Marc Rich & Co),16In re Grand Jury Subpoena (Marc Rich & Co), 736 F 2d 864 (2d Cir 1984). Richmark Corp v Timber Falling Consultants,17Richmark Corp v Timber Falling Consultants, 959 F 2d 1468 (9th Cir 1992). and Linde v Arab Bank, PLC18Linde v Arab Bank, PLC, 706 F 3d 92 (2d Cir 2013)., illustrate the fact-intensive comity balancing: courts have imposed sanctions, or declined to disturb them, even when compliance would violate foreign law, though foreign criminal exposure carries weight and good faith efforts to comply influence the sanctions calculus.
The Clarifying Lawful Overseas Use of Data Act (CLOUD Act) extends US extraterritorial reach further: US law enforcement may compel disclosure of data held by US-based service providers regardless of physical storage location.19Clarifying Lawful Overseas Use of Data Act, Pub L No 115-141, 132 Stat 1213 (2018), codified at 18 USC § 2713. No US-Swiss executive agreement exists under this framework. Companies storing privileged communications with US-headquartered cloud providers should recognize that Swiss server location provides less protection than the service provider relationship might suggest. Whether entrusting protected material to a US-headquartered provider is itself a disclosure for the purposes of Art. 321 StGB is debated among Swiss commentators, a question that arises before any foreign order is served.
5. What Role Does the Blocking Statute Play?
Swiss law adds another layer through Art. 271 of the Criminal Code, sometimes called the "blocking statute." This provision makes it a criminal offense to perform acts on Swiss territory on behalf of a foreign state that are reserved to Swiss governmental authorities.20Art. 271 StGB. The provision has been interpreted to cover certain evidence-gathering activities conducted in Switzerland for use in foreign legal proceedings.
The practical application of Art. 271 to discovery compliance is contested rather than benign. The provision bars the relevant act only where it is performed without authorization: a party may apply for a permit, and the competent authorities have granted such authorizations for the production of information to foreign civil courts. Absent that authorization, the risk is concrete: the Federal Tribunal has upheld a criminal conviction under Art. 271 where a financial intermediary transmitted client files directly to a foreign authority outside the mutual-assistance channel. Exposure is most acute where the materials contain identifiable third-party data or are routed to a foreign authority, and least settled where a party produces its own documents in private civil discovery. Formal discovery through Hague Convention channels, processed with Swiss governmental authorization, avoids Art. 271 issues entirely.
The Hague Convention on the Taking of Evidence Abroad provides a procedurally safer mechanism for obtaining Swiss-located evidence.21Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters (18 March 1970) 847 UNTS 231. The Convention has been in force for Switzerland since 1 January 1995. Swiss courts processing such requests apply Swiss law, including privilege rules. However, Switzerland's reservation under Art. 23 excludes execution of requests requiring pre-trial discovery as known in common law countries.22Switzerland, Declaration under Art. 23 Hague Evidence Convention (2 November 1994); Bundesamt für Justiz, Wegleitung für die internationale Rechtshilfe in Zivilsachen (3rd edn 2003). Broad discovery requests typical of US litigation will likely be refused; only requests for specific, identified documents may succeed. The Swiss-US Mutual Legal Assistance Treaty serves criminal matters only,23Treaty between the Swiss Confederation and the United States of America on Mutual Assistance in Criminal Matters (TEJUS), SR 0.351.933.6. and regulatory cooperation frameworks address enforcement rather than private litigation, leaving civil litigants without an institutional channel for resolving the conflict.
Swiss data protection law compounds the analysis. The DSG restricts transfers of personal data to countries lacking adequate protection,24Bundesgesetz über den Datenschutz (DSG) vom 25. September 2020 (SR 235.1), Art. 16–18. and documents subject to US discovery demands may contain personal data of Swiss employees or clinical trial participants, requiring legal bases independent of professional secrecy analysis. The interaction between Swiss data protection restrictions and cross-border obligations is examined in Insight 03.
The calculus shifts depending on how the company is situated. Where Swiss-held documents are central to the US litigation and the company has substantial US operations, US sanctions may pose the more immediate threat. Where documents are peripheral but the company has significant Swiss regulatory relationships, Swiss exposure and reputational consequences may predominate. No general formula resolves these competing pressures; each situation requires fact-specific assessment of where the greater jeopardy lies.
6. What Document Categories Are Most Exposed in Life Sciences Disputes?
Life sciences litigation generates discovery demands that systematically target document categories where Swiss professional secrecy and US disclosure obligations collide. Understanding these patterns before litigation arises allows companies to assess which Swiss-held materials carry the greatest cross-border exposure.
Clinical trial documentation and pharmacovigilance records present the highest-exposure categories. Clinical study reports, investigator brochures, and safety data submitted to Swissmedic may involve communications with Swiss medical advisors or Rechtsanwälte advising on regulatory strategy, communications that carry Art. 321 protection through independent professional relationships. Pharmacovigilance data is often central to US product liability claims, yet adverse event analyses compiled with input from Swiss-licensed physicians or pharmacists may carry the same protection. The distinction between raw reports and analyzed safety assessments prepared with professional advice is critical but often blurred in practice.
Regulatory correspondence and board materials present further exposure. Correspondence prepared with Swiss counsel involvement, or internal memoranda analyzing regulatory strategy with counsel input, may trigger Art. 321 concerns even where the underlying communications with Swissmedic are discoverable. Board presentations on regulatory risk or litigation exposure, frequently prepared with external Rechtsanwälte, may carry Art. 321 protection even though the business decisions they inform are not themselves privileged. The mixed-purpose nature of these documents creates document-by-document classification challenges that resist categorical resolution.
7. Where Do Pre-Litigation Choices Constrain Options?
Pre-Litigation Structure
The conflict between Swiss professional secrecy and US discovery obligations does not arise suddenly when litigation commences. It is latent in the structure of any life sciences company that maintains Swiss operations, uses Swiss counsel, or stores documents in Switzerland while conducting business that may generate US litigation exposure.
The location and routing of privileged communications shapes the analysis. Communications with US counsel face US discovery rules without Swiss complications, but also without Art. 321 protection. Communications with Swiss counsel receive Art. 321 protection but create the conflict scenario when US litigation occurs. Whether the company has considered how its advisory relationships allocate matters between jurisdictions, and whether those allocations reflect deliberate choices, may determine the options available when discovery demands arrive.
Whether the company has mapped these structural questions before litigation creates urgency (where Swiss-protected materials reside, whether in-house lawyers hold the registrations that determine their communications' protection level, whether external Swiss counsel have been consulted about their position on disclosure) shapes what protections exist and what procedural options remain available. Document retention practices interact with these questions: whether Swiss-protected materials are preserved exclusively in Switzerland rather than replicated to US-accessible systems determines whether production of US-held copies moots the Swiss law objection. Dispute-resolution architecture is a further pre-dispute lever: an arbitration clause, with the narrower tribunal-controlled production typical of international arbitration (for instance under the IBA Rules on the Taking of Evidence in International Arbitration), can keep a matter out of the broad discovery regime that generates the conflict in the first place.
Litigation Response
Once litigation is pending, the analysis shifts to mitigation. The approach to document production matters as much as the substantive objection. An all-or-nothing posture (refusing production of all Swiss-held documents regardless of whether they carry Art. 321 protection) receives less judicial sympathy than a differentiated response that demonstrates good-faith engagement with the competing obligations. Hague Convention procedures may reduce Swiss law exposure even when US courts are unlikely to require their use, and the record of having pursued alternative channels influences the comity analysis.
Protective orders negotiated in US proceedings can serve a mediating function, though they do not eliminate Swiss criminal exposure. Restricting access to Swiss-origin documents and tailoring confidentiality designations to reflect the producing party's Swiss law obligations may reduce the scope of disclosure in ways that Swiss supervisory authorities consider when evaluating authorization requests. US courts can structure tiered confidentiality designations under their protective-order authority, and the documented effort to minimize disclosure impact may influence the comity balancing test, even though courts applying that test have frequently compelled production over foreign-secrecy objections.25Fed R Civ P 26(c); in Strauss v Credit Lyonnais, SA, 242 FRD 199 (EDNY 2007), the court compelled production over a French blocking-statute objection under the § 442(1)(c) factors.
The structural limitation remains: a US protective order is enforceable through US contempt power, not Swiss law. It does not bind Swiss authorities and does not create a defense to Art. 321 prosecution. Its value lies in reducing practical risk: narrowing the audience for disclosed information and creating a record of good-faith accommodation, rather than in providing legal immunity. The tension persists, and the questions it raises require analysis tailored to specific facts, corporate structure, and commercial context.